Harmony Biosciences Management, Inc.

Harmony Biosciences Management, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. Harmony Biosciences Management, Inc. was formerly known as Zynerba Pharmaceuticals, Inc. and changed its name Harmony Biosciences Management, Inc. in July 2024. Harmony Biosciences Management, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. As of October 10, 2023, Harmony Biosciences Management, Inc. operates as a subsidiary of Harmony Biosciences Holdings, Inc.